What Allegra does

Allegra is a global over-the-counter allergy medication brand owned by Opella, the consumer healthcare division of Sanofi (spun off as a standalone entity in 2024 and formerly operating as Chattem, Inc. in the US). The brand manufactures and markets non-drowsy antihistamine products based on fexofenadine hydrochloride, a third-generation H1-receptor antagonist clinically proven to have 0% brain interference. Allegra's product portfolio spans adult tablets and gelcaps (12-hour and 24-hour formulations), Allegra-D combinations with pseudoephedrine for congestion, Allegra Hives for chronic idiopathic urticaria, and pediatric formulations including liquids and dissolve tabs for children ages 6 months and older. Regional variants are sold under the brand names Telfast, Allervia, and Allenasal in Europe, Asia-Pacific, Latin America, Africa, and the Middle East.

The brand operates a direct-to-consumer go-to-market model through allegra.com and 40+ country-specific portals, supplemented by a healthcare professional channel (hcpportal.hcpordering.com) for sample and coupon distribution that drives allergist and pediatrician recommendations. Products are sold OTC through major retail pharmacy chains (CVS, Walgreens), mass merchandisers (Walmart, Target), grocery stores, and e-commerce platforms. Revenue is generated through unit-pricing at retail with pay-as-you-go consumer purchases and no subscription or enterprise contract model. Allegra positions itself as the #1 allergist-recommended non-drowsy OTC antihistamine brand in the US and holds #1 brand status in Brazil, with consecutive Consumer Brand of the Year awards in South Korea (2023-2024).

The business model is classic OTC consumer healthcare: mass-market retail distribution, brand-driven demand generation through clinical evidence and professional endorsement, and seasonal recurring purchase patterns. Allegra targets adults and parents of children with seasonal and year-round allergies who prioritize cognitive performance and refuse to trade symptom relief for drowsiness. The brand differentiates from competitors like Claritin and Benadryl through its non-drowsy formulation, fast 1-hour onset, 24-hour duration, and proprietary clinical evidence including PET brain receptor occupancy studies.

Name

Allegra

Legal name

Chattem, Inc.

Website

https://allegra.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Allegra is a global OTC allergy medication brand owned by Opella (Sanofi's consumer health division), selling non-drowsy fexofenadine-based antihistamines for adults and children across 40+ countries under the Allegra, Telfast, and Allenasal names.

Ownership category

akta.pro rank

Product category

OTC Allergy Medication

akta.pro primary industry

Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• OTC allergy medication
• Antihistamine products
• Non-drowsy allergy relief
• Fexofenadine medications
• Pediatric allergy treatment

Headquarters

HQ city

Chattanooga

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

1. Consumer OTC Allergy Medication Sales: Allegra generates revenue through the sale of over-the-counter (OTC) allergy relief products including tablets, gelcaps, liquid suspensions, and decongestant combinations. Products are sold through retail pharmacies, mass merchandisers, grocery stores, and online e-commerce channels. The brand targets both adult and pediatric populations with various formulations.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Allegra manufactures and markets over-the-counter (OTC) non-drowsy allergy relief medications based on the active pharmaceutical ingredient fexofenadine hydrochloride. The product portfolio includes adult tablets and gelcaps in 12-hour and 24-hour formulations, pediatric liquid and dissolve-tab formulations, Allegra-D combination products with pseudoephedrine for nasal congestion, and specialized formulations for chronic idiopathic urticaria (hives). Products are sold under regional brand names including Allegra, Telfast, and Allenasal across 40+ countries.

Product overview

Allegra is an over-the-counter (OTC) allergy medication brand offering a comprehensive portfolio of non-drowsy antihistamine products for adults and children. The core product line includes Allegra® 24 Hour Tablets, Allegra® 12 Hour Tablets, and Allegra® 24 Hour Gelcaps containing fexofenadine as the active ingredient. The product range extends to Allegra-D® formulations combining fexofenadine with pseudoephedrine for allergy and congestion relief, Allegra® Hives tablets for chronic idiopathic urticaria, and children's formulations including liquid and dissolve tablets. Regional variants include Allegra® Pediátrico (Latin America) and Allegra® 120mg tablets (Korea, Ecuador, Colombia). Allegra positions itself as the #1 allergist-recommended non-drowsy brand, emphasizing its 0% brain interference formulation that allows users to stay alert while managing seasonal allergies, indoor allergies, and hives.

Differentiator

Problem solved

Functional benefit

Brands

• Allegra-D: Allegra-D combines fexofenadine with pseudoephedrine for allergy relief plus nasal congestion relief
• Children's Allegra
• Allegra Hives

Products and services

• Allegra 24 Hour Tablets

Quantifiable outcome

• Starts working in 1 hour — median onset of allergic rhinitis symptom relief is 1 hour for both fexofenadine 60mg and 180mg doses (Day JH et al., Ann Allergy Asthma Immunol. 1997)
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Marcus Ericsson (IndyCar Driver)minorGTM or Marketing PartnerMarcus Ericsson, 2022 Indy 500 winner and IndyCar driver, has a partnership with Allegra allergy medication. The partnership highlights Allegra's non-drowsy benefit for high-performance individuals who need to stay mentally sharp. Ericsson discusses using Allegra to stay mentally sharp while driving at high speeds, demonstrating the product's cognitive performance advantage. This athlete partnership serves as a brand ambassador relationship to reinforce Allegra's core differentiator of zero brain interference.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Zyrtec: Zyrtec (cetirizine), marketed by Kenvue (spun out of Johnson & Johnson), is Allegra's primary direct competitor in the non-drowsy OTC antihistamine category. Both target adult and pediatric allergy sufferers with similar claims around 24-hour relief and minimal sedation, making them the closest head-to-head brand rival across US and global markets.
• Claritin: Claritin (loratadine), owned by Bayer, is a second-generation OTC antihistamine positioned for non-drowsy 24-hour relief. It competes with Allegra across the same adult and pediatric allergy segments in North America, Latin America, and Europe, often at lower price points due to earlier market entry.
• Benadryl: Benadryl (diphenhydramine), marketed by Kenvue, is a first-generation OTC antihistamine used for allergy symptoms though it causes significant drowsiness. Despite its sedating profile, it remains a major brand in the category and directly competes with Allegra for allergy-relief shelf space and consumer dollar share.
• Xyzal Allergy 24HR: Xyzal (levocetirizine), marketed by Chattem/Sanofi in the US and UCB internationally, is a third-generation OTC antihistamine marketed for nighttime allergy relief. It is closely comparable to Allegra in non-drowsy positioning and even overlaps in ownership via Opella/Chattem in the US market.
• Aerius: Aerius (desloratadine), marketed by Organon (formerly Merck), is a third-generation antihistamine offered as an OTC in Canada and various international markets under names including Aerius, Neoclarityn, and Clarinex. It competes with Allegra in the prescription-to-OTC switch category and shares similar non-drowsy positioning.
• Alavert: Alavert (loratadine), marketed by Foundation Consumer Healthcare, is an OTC non-drowsy allergy medicine sold primarily in the US. It targets the same consumer segments and product positioning as Allegra but competes primarily on price and convenience.
• Tavist Allergy: Tavist Allergy (clemastine), marketed by Prestige Consumer Healthcare, is an OTC antihistamine competing in the same allergy relief category as Allegra. It targets similar adult allergy sufferers with comparable claims about symptom relief and is a competing brand on US pharmacy shelves.

Regional players

• Reactine: Reactine (cetirizine), owned by Church & Dwight after the Bayer Consumer Health acquisition, is the leading OTC allergy brand in Canada and competes head-to-head with Allegra Canada in the Canadian market. Comparable product positioning and target consumer make it a direct competitive analogue for the North American region.

Broad incumbents

• Flonase Allergy Relief: Flonase (fluticasone), owned by Haleon (spun out of GSK), is a leading intranasal corticosteroid for allergy symptom relief. While a different delivery modality, it competes with Allegra for the same consumer allergy budget and is part of Haleon's broader consumer healthcare allergy/respiratory portfolio.
• Rhinocort Allergy: Rhinocort (budesonide), marketed by Kenvue, is an OTC intranasal corticosteroid spray for allergic rhinitis. It serves the same allergy symptom category as Allegra through an alternative (topical) modality and competes for share-of-voice and shelf placement in the broader allergy relief category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Allegra
• LinkedInlinkedin.com/company/allegra-models-agency-mexico
• Instagraminstagram.com/allegra
• Xx.com/allegraotc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allegra